Company: SHPH
Filing Date: 2025-01-24
Form Type: 424B3
Source: 0001493152-25-003508
Chunk: 155

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-24
Form: 424B3
Chunk 155
---
arrants Offering

In October 2024, we sold a total of $831,579
of 5% original issue discount senior secured convertible notes, which notes convert into 732,134 shares of common stock, subject to adjustment,
and warrants to purchase 329,461 shares of common stock exercisable at a variable-weighted average of $1.42 per share. The convertible
notes have a term of one year, are may be converted at any time by the holder and are subject to mandatory conversion at the end of the
one-year holding period in the event the convertible notes are registered. The warrants have a term of five years and contain standard
anti-dilution protections.

October 2024 Public Offering Warrants

In conjunction with our October 2024
public offering, we issued pre-funded warrants to purchase 2,555,246 shares of common stock exercisable at $0.001 per share, and
warrants to purchase a total of 2,950,820 shares of common stock exercisable at $1.40 per share. The warrants are exercisable, at the
option of the holder, for a period of five years and are subject to a 4.99% ownership limitation. However, any holder may increase
or decrease such percentage so long as it does not exceed 9.99%. The pre-funded warrants and warrants are not transferrable without
the consent of the Company and the holders have no voting rights until the warrants are exercised.

Anti-Takeover Effects of Provisions of our Certificate of Incorporation, our Bylaws and Delaware Law

Some provisions of Delaware law, our certificate of incorporation and our bylaws contain provisions that could make the following transactions more difficult: acquisition of us by means of a tender offer; acquisition of us by means of a proxy contest or otherwise; or removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions that might result in a premium over the market price for our shares.

These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our Board of Directors. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of a non-friendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discour